We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with ...
Clinical Phase Biopharmaceuticals company Cascadian Therapeutics today announced a review of recent advances in tucatinib, an investigational oral small molecule kinase inhibitor